Stocks in Focus

BH Rises Over 13% Ahead of Apple’s Foldable Phone Unveiling… Expectations of Component-Related Gains [Featured Stock]

Shin Ha-yeon
2026-09-01 09:42:58
[Edaily Reporter Shin Ha-yeon ] BH(090460)is surging in early trading amid growing expectations that it will benefit from Apple’s upcoming unveiling of a foldable phone. Expectations of securing new clients in the robotics and humanoid sectors are also boosting the stock price.

According to MP Doctor on the 1st, as of 9:35 a.m., BH is trading at 20,600 won, up 13.0% from the previous trading day.
(Photo: BH)

With Apple expected to unveil a foldable phone this month, expectations that BH—a supplier of flexible printed circuit boards (FPCBs)—will benefit from this development have come to the fore. Following strong sales of SamsungElectronics’ Galaxy Z Fold 8, the global foldable phone market is projected to enter a phase of full-scale growth as Apple joins the fray.

In a report released today, DaishinSecurities projected that global foldable phone shipments will reach 26.1 million units this year—a 28.4% increase from the previous year—and will rise by 35.5% to 35.37 million units in 2027. The firm predicted that SamsungElectronics will expand its lineup of foldable phone models from the current three to five next year, and that Apple’s foldable phones will also record annual sales of over 15 million units.

Expectations for business expansion into the robotics and humanoid sectors have also grown. BH is already generating revenue based on Boston Dynamics’ humanoid robot “Atlas,” and is expected to add new North American clients this month. With long-lead flexible PCBs being applied to robot joints and other components, related revenue is projected to take off in earnest after 2027.

Park Kang-ho, an analyst at DaishinSecurities, noted, “The company is expected to benefit from the expansion of the foldable phone market by Apple and SamsungElectronics,” adding, “With the anticipated addition of new North American clients in the robotics and humanoid sectors, the stock is likely to undergo another round of valuation reassessment.” He maintained a “Buy” rating and a target price of 41,000 won.

He further emphasized, “The price-to-earnings ratio (PER) for 2026 stands at around 5 times, which is a historic low,” adding, “Considering strong earnings, the undervalued valuation, and business diversification into robots and humanoids, we expect the stock price to rebound and rise in September.”

Economy

Corporation

IT·Science

Economy

[VC's Pick] LegalTech Firm 'Legora' Expands into Korea, Secures Series E Funding

This week (October 19–23), startups in various sectors—including accommodation solutions, AI video production, and digital healthcare—secured investments from venture capital (VC) firms and accelerato…
2026-10-24 13:07:04

Corporation

“Are All Medications the Same for a Runny Nose and Sneezing?”… The Differences Between Zyrtec, Allegra, and AllerShot [Medicine 101]

During seasonal transitions, when the temperature difference between morning and evening widens, more people complain of sneezing, a clear runny nose, and itchy noses and eyes. While it’s easy to mist…
2026-10-24 08:59:02

IT·Science

Rokit Healthcare Plunges 20% Following FDA Warning Letter to U.S. Partner [K-bio Pulse]

Korean small-cap pharma, biotech, and healthcare stocks moved in opposite directions on Oct. 22, as large-cap chipmakers weakened. Rokit Healthcare posted the steepest decline on the KOSDAQ, while in-…
2026-10-24 06:17:02